ELIGARD 22.5/45 mg is indicated for the treatment of hormone-dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
Composition: One prefilled syringe with powder for solution for injection contains 45 mg leuprorelin acetate, equivalent to 41.7 mg leuprorelin.
